Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2018

View Archived Issues

AzurRx BioPharma's AZ-1103 safe and biologically active in preclinical model

Pfizer enrolling patients in phase III trial of glasdegib for the treatment of AML

Merck KGaA presents potent and selective ATM kinase inhibitor M-3541

FDA clears IND application for phase I/II study of OBI-3424

KB-103 receives orphan medicinal product designation in Europe

Shire and Takeda in discussions after Shire rejects three Takeda proposals for company

Pfizer's novel ADC CD123-CPI has broad potential for treating acute myeloid leukemia

FDA grants orphan drug designation for Oraxol for the treatment of angiosarcoma

Argos Therapeutics discontinues ADAPT study based on interim analysis results

FDA grants fast track designation for balixafortide plus eribulin for metastatic breast cancer

Phase II E4 Relief study of Donesta achieves primary objective

ApolloBio obtains license to Toca 511/Toca FC for greater China region

CD163, VCAM-1 identified as markers of liver injury in autoimmune hepatitis

Goofice tablet launched in Japan

Otsuka launches Rexulti in Japan

First-in-human study of FS-118 in advanced solid tumors enrolling subjects

FDA accepts Veloxis' sNDA for Envarsus XR

ADC Therapeutics presents potent antitumoral compounds in xenograft models

Johnson & Johnson reviews progress of first quarter 2018

FDA advisory committee recommends approval of Epidiolex for LGS and Dravet syndrome

Novel genetically altered broadly neutralizing antibodies protect monkeys from SHIV

EMA committee hands down negative opinion for masitinib in ALS

Relay Therapeutics and collaborator patent PTP-2C inhibitors

Plexxikon divulges novel IDO1 and/or TDO inhibitors

Vertex Pharmaceuticals identifies new PAR-2 antagonists

Medshine Discovery patents MAPK 14 inhibitors

Mission Therapeutics presents novel USP30 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...